Newbury Pharmaceuticals (NEWBRY) Q2 2025 earnings summary

Executive summary

• Net revenue for Q2 increased to SEK 12,434 thousand from SEK 3,135 thousand year-over-year, with interim period revenue at SEK 18,972 thousand, up from SEK 14,320 thousand.

• EBITDA loss narrowed to SEK -973 thousand in Q2 from SEK -4,147 thousand, and to SEK -4,732 thousand for the interim period from SEK -6,881 thousand.

• Nordic sales showed strong momentum, with Desmopressin gaining market share and new tender sales secured; international sales contributed SEK 2,942 thousand in Q2.

• Product portfolio expansion continued, with several new generic approvals and a strengthened distribution partnership for four additional products.

Financial highlights

• Operating result (EBIT) for Q2 improved to SEK -1,443 thousand from SEK -4,583 thousand; interim EBIT at SEK -5,672 thousand versus SEK -7,681 thousand.

• Result after tax for Q2 was SEK -1,851 thousand, compared to SEK -4,961 thousand year-over-year.

• Cash position at period end was SEK 12,857 thousand, up from SEK 6,412 thousand.

• Operating cash flow for Q2 was SEK -6,371 thousand, improving from SEK -7,977 thousand; interim operating cash flow at SEK -1,579 thousand versus SEK -13,655 thousand.

• Investments in the quarter totaled SEK 203 thousand, down from SEK 1,279 thousand.

Outlook and guidance

• On track to expand product portfolio to 20-25 products by end of 2025, with new launches expected in H2 2025.

• EBITDA break-even projected at sales level of SEK 15-18 million.

• Preparing for entry into Finland, with first hospital tenders submitted and further launches planned for H2 2025.